Increased Metabolic Activity on 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Human Immunodeficiency Virus-Associated Immune Reconstitution Inflammatory Syndrome.
Adult
Anti-HIV Agents
/ adverse effects
Biomarkers
Female
Fluorodeoxyglucose F18
Gene Expression Regulation
/ drug effects
Glucose Transporter Type 1
/ genetics
HIV Infections
/ complications
Humans
Immune Reconstitution Inflammatory Syndrome
/ diagnostic imaging
Male
Monocytes
/ metabolism
Positron Emission Tomography Computed Tomography
Radiopharmaceuticals
/ pharmacology
T-Lymphocytes
/ metabolism
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
07 01 2019
07 01 2019
Historique:
received:
03
03
2018
accepted:
23
05
2018
pubmed:
15
9
2018
medline:
31
1
2020
entrez:
15
9
2018
Statut:
ppublish
Résumé
Immune reconstitution inflammatory syndrome (IRIS) represents an unexpected inflammatory response shortly after initiation of antiretroviral therapy (ART) in some human immunodeficiency virus (HIV)-infected patients with underlying neoplasia or opportunistic infections, including tuberculosis. We hypothesized that IRIS is associated with increased glycolysis and that 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) could help identify high-risk subjects. In this prospective cohort study, 30 HIV-infected patients (CD4+ count <100 cells/µL) underwent FDG-PET/CT scans at baseline and 4-8 weeks after ART initiation. Ten patients developed IRIS (6 mycobacterial). At baseline, total glycolytic activity, total lesion volume, and maximum standardized uptake values (SUVs) of pathologic FDG uptake (reflective of opportunistic disease burden) were significantly higher in IRIS vs non-IRIS (P = .010, .017, and .029, respectively) and significantly correlated with soluble inflammatory biomarkers (interferon-γ, myeloperoxidase, tumor necrosis factor, interleukin 6, soluble CD14). Baseline bone marrow (BM) and spleen FDG uptake was higher in mycobacterial IRIS specifically. After ART initiation, BM and spleen mean SUV decreased in non-IRIS (P = .004, .013) but not IRIS subjects. Our results were supported by significantly higher glucose transporter 1 (Glut-1) expression of CD4+ cells and monocytes after ART initiation in IRIS/mycobacterial IRIS compared with non-IRIS patients. We conclude that increased pathologic metabolic activity on FDG-PET/CT prior to ART initiation is associated with IRIS development and correlates with inflammatory biomarkers. Abnormally elevated BM and spleen metabolism is associated with mycobacterial IRIS, HIV viremia, and Glut-1 expression on CD4+ cells and monocytes. NCT02147405.
Sections du résumé
Background
Immune reconstitution inflammatory syndrome (IRIS) represents an unexpected inflammatory response shortly after initiation of antiretroviral therapy (ART) in some human immunodeficiency virus (HIV)-infected patients with underlying neoplasia or opportunistic infections, including tuberculosis. We hypothesized that IRIS is associated with increased glycolysis and that 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) could help identify high-risk subjects.
Methods
In this prospective cohort study, 30 HIV-infected patients (CD4+ count <100 cells/µL) underwent FDG-PET/CT scans at baseline and 4-8 weeks after ART initiation. Ten patients developed IRIS (6 mycobacterial).
Results
At baseline, total glycolytic activity, total lesion volume, and maximum standardized uptake values (SUVs) of pathologic FDG uptake (reflective of opportunistic disease burden) were significantly higher in IRIS vs non-IRIS (P = .010, .017, and .029, respectively) and significantly correlated with soluble inflammatory biomarkers (interferon-γ, myeloperoxidase, tumor necrosis factor, interleukin 6, soluble CD14). Baseline bone marrow (BM) and spleen FDG uptake was higher in mycobacterial IRIS specifically. After ART initiation, BM and spleen mean SUV decreased in non-IRIS (P = .004, .013) but not IRIS subjects. Our results were supported by significantly higher glucose transporter 1 (Glut-1) expression of CD4+ cells and monocytes after ART initiation in IRIS/mycobacterial IRIS compared with non-IRIS patients.
Conclusions
We conclude that increased pathologic metabolic activity on FDG-PET/CT prior to ART initiation is associated with IRIS development and correlates with inflammatory biomarkers. Abnormally elevated BM and spleen metabolism is associated with mycobacterial IRIS, HIV viremia, and Glut-1 expression on CD4+ cells and monocytes.
Clinical Trials Registration
NCT02147405.
Identifiants
pubmed: 30215671
pii: 5095310
doi: 10.1093/cid/ciy454
pmc: PMC6321853
doi:
Substances chimiques
Anti-HIV Agents
0
Biomarkers
0
Glucose Transporter Type 1
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Banques de données
ClinicalTrials.gov
['NCT02147405']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-238Subventions
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Références
Sci Rep. 2015 Dec 10;5:18176
pubmed: 26658723
Front Immunol. 2015 Jan 22;6:1
pubmed: 25657648
J Immunol. 2014 Dec 1;193(11):5595-603
pubmed: 25367121
Nat Med. 2016 Oct;22(10):1090-1093
pubmed: 27595321
J Nucl Med. 2011 Jun;52(6):880-5
pubmed: 21571788
Am J Respir Crit Care Med. 2012 Aug 15;186(4):369-77
pubmed: 22700860
Pharmacol Ther. 2009 Jan;121(1):29-40
pubmed: 18992769
Acta Clin Belg. 2011 Nov-Dec;66(6):419-21
pubmed: 22338303
Retrovirology. 2007 May 15;4:31
pubmed: 17504522
JMIR Res Protoc. 2016 Aug 29;5(3):e173
pubmed: 27571786
Curr Opin HIV AIDS. 2016 Mar;11(2):191-200
pubmed: 26720550
Curr HIV/AIDS Rep. 2014 Sep;11(3):223-32
pubmed: 24950732
Jpn J Radiol. 2010 Apr;28(3):231-4
pubmed: 20437136
N Engl J Med. 2017 Jul 20;377(3):283-284
pubmed: 28723319
AIDS. 2010 Sep 24;24(15):2381-90
pubmed: 20808204
Arthritis Rheum. 2004 Apr;50(4):1233-8
pubmed: 15077306
Science. 2016 Oct 28;354(6311):481-484
pubmed: 27708054
J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):423-8
pubmed: 24226057
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139
pubmed: 29514234
Bioessays. 2013 Nov;35(11):965-73
pubmed: 24115022
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Neoplasia. 2005 Apr;7(4):369-79
pubmed: 15967114
N Engl J Med. 2011 Oct 20;365(16):1492-501
pubmed: 22010915
Eur J Immunol. 2016 Jan;46(1):13-21
pubmed: 26643360
Curr Opin Pulm Med. 2014 May;20(3):287-93
pubmed: 24614238
Sci Rep. 2016 Apr 12;6:24129
pubmed: 27067254
Immunology. 2015 Aug;145(4):498-507
pubmed: 25807843
Semin Nucl Med. 2013 Sep;43(5):349-66
pubmed: 23905617
PLoS Pathog. 2014 Oct 02;10(10):e1004433
pubmed: 25275318
HIV Med. 2013 Sep;14(8):455-62
pubmed: 23517190
N Engl J Med. 2011 Oct 20;365(16):1471-81
pubmed: 22010913